Skip to main content
. 2022 Sep 15;27(18):6000. doi: 10.3390/molecules27186000

Figure 1.

Figure 1

The clinical values of ALDH2 in prostate cancer. (A) Venn plot showing through the intersection of DEGs of TCGA database and GEO datasets, and gene sets of fatty acid metabolism; (B) Kaplan–Meier curve of ALDH2 for BCR-free survival; (C) Kaplan–Meier curve of ALDH2 for metastasis-free survival; (D) Kaplan–Meier curve of ALDH2 for BCR-free survival in TCGA database; (E) volcano plot showing DEGs in TCGA database; (F) volcano plot showing DEGs in GEO datasets; (G) differential expression of ALDH2 between tumor and normal tissues at protein level; (H) differential mRNA expression of ALDH2 between tumor and normal sample at pan-cancer level in TCGA database; (I) comparison between ALDH2 and T stages; (J) comparison between ALDH2 and Gleason score; (K) comparison between ALDH2 and BCR; (L) ROC curve of ALDH2 discriminating BCR from no BCR; (M) comparison between ALDH2 and Gleason score in TCGA database; (N) comparison between ALDH2 and T stages in TCGA database; (O) comparison between ALDH2 and N stages in TCGA database; (P) ROC curve of discriminating drug resistance from drug sensitivity; and (Q) ROC curve of discriminating radiation resistance from radiation sensitivity. DEG = differentially expressed genes; BCR = biochemical recurrence; ROC= receiver operating characteristic curve. ns, 0.05; *, 0.05; **, 0.01, and ***, 0.001.